JP2018527322A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527322A5 JP2018527322A5 JP2018502770A JP2018502770A JP2018527322A5 JP 2018527322 A5 JP2018527322 A5 JP 2018527322A5 JP 2018502770 A JP2018502770 A JP 2018502770A JP 2018502770 A JP2018502770 A JP 2018502770A JP 2018527322 A5 JP2018527322 A5 JP 2018527322A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- biofilm
- skin
- disorder
- innate immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 29
- 230000036737 immune function Effects 0.000 claims description 11
- 230000008591 skin barrier function Effects 0.000 claims description 11
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 7
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 7
- 230000000975 bioactive effect Effects 0.000 claims description 7
- 230000004071 biological effect Effects 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 230000001270 agonistic effect Effects 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 claims description 4
- 230000000249 desinfective effect Effects 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 230000004682 mucosal barrier function Effects 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000027244 Dysbiosis Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 102100028314 Filaggrin Human genes 0.000 claims description 2
- 101710088660 Filaggrin Proteins 0.000 claims description 2
- 102100037009 Filaggrin-2 Human genes 0.000 claims description 2
- 101710095953 Filaggrin-2 Proteins 0.000 claims description 2
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 claims description 2
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 claims description 2
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 102000004125 Interleukin-1alpha Human genes 0.000 claims description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 102100031784 Loricrin Human genes 0.000 claims description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 claims description 2
- 102000014509 cathelicidin Human genes 0.000 claims description 2
- 108060001132 cathelicidin Proteins 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000007140 dysbiosis Effects 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 210000001650 focal adhesion Anatomy 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 102000046975 human DEFB1 Human genes 0.000 claims description 2
- 102000055779 human DEFB103A Human genes 0.000 claims description 2
- 102000049262 human DEFB4A Human genes 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000015788 innate immune response Effects 0.000 claims description 2
- 229940028885 interleukin-4 Drugs 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 102000007236 involucrin Human genes 0.000 claims description 2
- 108010033564 involucrin Proteins 0.000 claims description 2
- 108010079309 loricrin Proteins 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 229960003085 meticillin Drugs 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000002992 thymic effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000002912 lymphogenic effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562194630P | 2015-07-20 | 2015-07-20 | |
| US62/194,630 | 2015-07-20 | ||
| PCT/US2016/042939 WO2017015275A1 (en) | 2015-07-20 | 2016-07-19 | Materials and methods for improving immune responses and the skin and/or mucosal barrier function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018527322A JP2018527322A (ja) | 2018-09-20 |
| JP2018527322A5 true JP2018527322A5 (https=) | 2018-11-01 |
| JP6727285B2 JP6727285B2 (ja) | 2020-07-22 |
Family
ID=57835147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502770A Active JP6727285B2 (ja) | 2015-07-20 | 2016-07-19 | 免疫応答ならびに皮膚および／または粘膜バリア機能を改善するための材料および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US9706778B2 (https=) |
| EP (1) | EP3324986B1 (https=) |
| JP (1) | JP6727285B2 (https=) |
| KR (1) | KR102258415B1 (https=) |
| CN (1) | CN108135947B (https=) |
| AU (1) | AU2016297539B9 (https=) |
| BR (1) | BR112018001187B1 (https=) |
| CA (1) | CA2991990C (https=) |
| DK (1) | DK3324986T3 (https=) |
| ES (1) | ES2904555T3 (https=) |
| HU (1) | HUE057494T2 (https=) |
| IL (1) | IL256973B (https=) |
| MX (1) | MX395076B (https=) |
| PL (1) | PL3324986T3 (https=) |
| PT (1) | PT3324986T (https=) |
| WO (1) | WO2017015275A1 (https=) |
| ZA (1) | ZA201800209B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5548121B2 (ja) | 2007-05-14 | 2014-07-16 | リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク | バイオフィルム中の細菌細胞における生理学的分散応答の誘導 |
| DK3324986T3 (da) * | 2015-07-20 | 2022-01-31 | Quorum Innovations Llc | Materialer og fremgangsmåder til forbedring af immunreaktioner og hud- og/eller slimhindebarrierefunktion |
| WO2018146550A1 (en) | 2017-02-10 | 2018-08-16 | De Maio Domingos Mauricio | Methods and systems for preventing, correcting, transforming, and modifying facial, aesthetics, and consulting patients regarding the same |
| US11253454B2 (en) * | 2017-03-10 | 2022-02-22 | Johnson & Johnson Consumer Inc. | Method for affecting touch |
| GB201807576D0 (en) | 2018-05-09 | 2018-06-20 | Skinbiotherapeutics Plc | Compositions and uses thereof |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| EP3685669A1 (en) * | 2019-01-23 | 2020-07-29 | Chrisal NV | Composition for the decontamination and inoculation of surfaces |
| EP3741398A1 (en) * | 2019-05-20 | 2020-11-25 | Medizinische Hochschule Hannover | Method for coating a medical device and coated medical device |
| MX2022006163A (es) * | 2019-11-26 | 2022-06-17 | Quorum Innovations Llc | Nuevas composiciones de barrera protectora y usos de las mismas. |
| CA3176797A1 (en) * | 2020-05-06 | 2021-11-11 | Nicholas T. Monsul | Novel protein, and therapeutic and cosmetic uses thereof |
| KR102167387B1 (ko) * | 2020-05-14 | 2020-10-19 | 코스맥스 주식회사 | 피부 장벽 강화, 피부 보습 또는 항노화를 위한 조성물 |
| EP4161558A4 (en) * | 2020-06-06 | 2024-06-19 | Quorum Innovations, LLC | Materials and methods for inhibiting a viral infection, including a coronavirus infection |
| CA3193765A1 (en) * | 2020-09-29 | 2022-04-07 | Anindya Dasgupta | A personal care composition comprising amino acids |
| KR102573754B1 (ko) * | 2021-02-25 | 2023-09-01 | 주식회사 차메디텍 | 신규의 펩타이드 및 이를 포함하는 피부장벽 강화 또는 피부가려움증 억제를 위한 화장료 조성물 |
| KR102389749B1 (ko) * | 2021-05-14 | 2022-04-22 | 주식회사 세바바이오텍 | 피부장벽강화 및 항주름 활성을 갖는 피부 유래 락토바실러스 퍼멘텀 아종 세바１０１ 균주 및 이의 용도 |
| CN113832050B (zh) * | 2021-08-13 | 2022-10-21 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 一株高效合成烟酰胺、抗光老化的发酵乳杆菌xjc60及其应用 |
| CN114717162A (zh) * | 2022-05-17 | 2022-07-08 | 廖梅香 | 发酵乳杆菌及其应用 |
| CN118126875B (zh) * | 2024-02-05 | 2024-11-05 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一株表皮葡萄球菌及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPS057102A0 (en) * | 2002-02-15 | 2002-03-07 | Vri Biomedical Ltd | Compositions and methods for treatment of skin disorders |
| US20050014729A1 (en) * | 2003-07-16 | 2005-01-20 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| EP1736537A1 (en) * | 2005-06-22 | 2006-12-27 | OrganoBalance GmbH | Methods and means for protecting the skin against pathogenic microorganisms |
| JP2007284360A (ja) * | 2006-04-13 | 2007-11-01 | Mitsukan Group Honsha:Kk | 乳酸菌由来のｐｐａｒ依存的遺伝子転写活性化組成物 |
| RU2009125184A (ru) * | 2006-12-01 | 2011-01-10 | Органобэлэнс Гмбх (De) | Композиции, наборы и их применения для защиты кожи от патогенных микроорганизмов |
| EP2227239A2 (en) * | 2007-12-06 | 2010-09-15 | Arla Foods Amba | Probiotic bacteria and regulation of fat storage |
| CZ2009724A3 (cs) * | 2009-11-04 | 2011-02-09 | Bio Agens Research And Development - Bard, S.R.O. | Protiplísnová smes s houbovým organismem Pythium oligandrum |
| AU2011241175A1 (en) * | 2010-04-16 | 2012-11-29 | Davos Life Science Pte. Ltd. | Synergistic interaction of at least one Vitamin E component and tyrosinase inhibitors for dermatological applications |
| CN103415531B (zh) * | 2011-02-09 | 2016-10-26 | 器官平衡有限责任公司 | 用于治疗皮肤病症的肽 |
| CN103687604A (zh) | 2011-03-01 | 2014-03-26 | 群体创新有限责任公司 | 用于治疗与致病生物膜相关之病症的材料和方法 |
| CN102226157B (zh) * | 2011-05-06 | 2013-01-09 | 北京龙科方舟生物工程技术有限公司 | 一株发酵乳杆菌及其应用 |
| KR20150000867A (ko) | 2011-12-07 | 2015-01-05 | 칼피스가부시키가이샤 | 유산균 또는 그 처리물을 포함한 지질대사 및/또는 당대사 개선제 |
| DK3324986T3 (da) * | 2015-07-20 | 2022-01-31 | Quorum Innovations Llc | Materialer og fremgangsmåder til forbedring af immunreaktioner og hud- og/eller slimhindebarrierefunktion |
-
2016
- 2016-07-19 DK DK16828408.1T patent/DK3324986T3/da active
- 2016-07-19 JP JP2018502770A patent/JP6727285B2/ja active Active
- 2016-07-19 BR BR112018001187-8A patent/BR112018001187B1/pt active IP Right Grant
- 2016-07-19 WO PCT/US2016/042939 patent/WO2017015275A1/en not_active Ceased
- 2016-07-19 MX MX2018000870A patent/MX395076B/es unknown
- 2016-07-19 HU HUE16828408A patent/HUE057494T2/hu unknown
- 2016-07-19 KR KR1020187004769A patent/KR102258415B1/ko active Active
- 2016-07-19 CN CN201680042640.6A patent/CN108135947B/zh active Active
- 2016-07-19 CA CA2991990A patent/CA2991990C/en active Active
- 2016-07-19 PL PL16828408T patent/PL3324986T3/pl unknown
- 2016-07-19 PT PT168284081T patent/PT3324986T/pt unknown
- 2016-07-19 ES ES16828408T patent/ES2904555T3/es active Active
- 2016-07-19 EP EP16828408.1A patent/EP3324986B1/en active Active
- 2016-07-19 AU AU2016297539A patent/AU2016297539B9/en active Active
- 2016-08-02 US US15/226,226 patent/US9706778B2/en active Active
-
2017
- 2017-04-25 US US15/496,686 patent/US10004772B2/en active Active
- 2017-06-21 US US15/629,439 patent/US10617726B2/en active Active
-
2018
- 2018-01-11 ZA ZA2018/00209A patent/ZA201800209B/en unknown
- 2018-01-17 IL IL256973A patent/IL256973B/en active IP Right Grant
-
2020
- 2020-03-02 US US16/806,000 patent/US11564957B2/en active Active
-
2023
- 2023-01-28 US US18/161,046 patent/US12440521B2/en active Active
-
2025
- 2025-10-10 US US19/354,958 patent/US20260034184A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018527322A5 (https=) | ||
| JP6727285B2 (ja) | 免疫応答ならびに皮膚および／または粘膜バリア機能を改善するための材料および方法 | |
| US10449222B2 (en) | Method for preventing and/or treating infections, colonisations, or illnesses related to Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pyogenes, Enterococcus faecium, Enterobacter cloacae, Proteus mirabilis, Bacteroides fragilis, Staphylococcus epidermidis, Propionibacterium acnes, Candida albicans and/or Malassezia furfur | |
| Davis et al. | Cosmeceuticals and natural products: wound healing | |
| KR20120036526A (ko) | 항균 펩타이드의 피부 세포 재생 촉진제로서의 신규한 용도 | |
| JP2022501330A5 (https=) | ||
| CN106589088B (zh) | 一种具有抗菌抗炎活性的多肽及其应用 | |
| JP2010241786A (ja) | ハチ毒を有効成分とする創傷又は火傷治療用組成物 | |
| JP7045671B2 (ja) | 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材 | |
| US10842827B2 (en) | Treatment and compound for epithelial wounds | |
| Han et al. | Somatic cell count in milk of bee venom treated dairy cows with mastitis | |
| WO2023118327A1 (en) | Live bacteria as excipients for proteins | |
| Teymouri et al. | The relationship between the skin microbiome and probiotics in the healing of burn injuries | |
| Abdurasulova et al. | The protective effect of Enterococcus faeciumL-3 in experimental allergic encephalomyelitis in rats is dose-dependent | |
| CN104436168A (zh) | 一种促进细胞再生的组合物及其制备方法和用途 | |
| TW202228667A (zh) | 慢性傷口癒合之二組分組合物 | |
| KR102852126B1 (ko) | 신규 펩타이드 및 이를 포함하는 상처 치료용 조성물 | |
| Faming et al. | Effect of enzymatic hydrolysis from mantle of pearl oyster on skin wound healing | |
| Dare et al. | The Influence of Prolonged Administration of Honey on Testicular and Prostate Architectures in Adult Wistar Rats | |
| Arooj et al. | The Biological Significance of Manuka Honey | |
| TH141466A (th) | โพลีเปปไทด์อนุพันธ์ lL-2 ที่มีแอคทิวิตี้อะโกนิสต์สำหรับการบำบัดมะเร็ง และการติดเชื้อเรื้อรัง |